Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HSV 1716

Drug Profile

HSV 1716

Alternative Names: Herpes simplex virus 1716 - Virttu; HSV1716; Oncolytic HSV-1716; Seprehvir

Latest Information Update: 29 Mar 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crusade Laboratories
  • Developer Nationwide Children's Hospital; Pediatric Brain Tumor Consortium; Virttu Biologics
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mesothelioma
  • Phase I Solid tumours
  • Preclinical Prostate cancer
  • No development reported Glioblastoma; Glioma; Malignant melanoma; Squamous cell cancer

Most Recent Events

  • 29 Mar 2018 HSV 1716 is still in phase I trials for Solid Tumours (Second line therapy or greater, In adolescent, In adults, In children) in USA (Intratumoural; IV) (NCT00931931)
  • 19 Mar 2018 Nationwide Children's Hospital completes a phase I trial in Solid Tumours (Second line therapy or greater, In adolescent, In adults, In children) in USA (Intratumoural; IV) (NCT00931931)
  • 05 Mar 2018 Sorrento Therapeutics plans a clinical trial for Cancer (Combination therapy) in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top